SCHEMBL8564013

SCHEMBL8564013

Nc1ccc(Sc2nc3cc(Cl)ccc3s2)cc1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ PPARA Q07869 6/20 0.48
▸ LOXL2 Q9Y4K0 1/20 0.48
▸ IDO1 P14902 1/20 0.48
▸ MAPT P10636 1/20 0.45
▸ FBP1 P09467 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ ALOX5 P09917 2/20 0.44
▸ TMEM97 Q5BJF2 2/20 0.43
▸ GLB1 P16278 1/20 0.43
▸ CTRC Q99895 1/20 0.43
▸ APP P05067 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10647219 0.88 APP (0.56) SMN1; SMN2NPSR1PPARAMAPTFBP1
SCHEMBL8560277 0.82 SMN1; SMN2 (0.59) SMN1; SMN2NPSR1PPARALOXL2IDO1
SCHEMBL12585031 0.80 SMN1; SMN2 (0.56) SMN1; SMN2NPSR1PPARALOXL2IDO1
SCHEMBL12584997 0.79 SMN1; SMN2 (0.58) SMN1; SMN2NPSR1PPARALOXL2IDO1
SCHEMBL8563621 0.78 FBP1 (0.58) SMN1; SMN2NPSR1MAPTFBP1APP
SCHEMBL8523609 0.77 SMN1; SMN2 (0.74) SMN1; SMN2NPSR1PPARALOXL2IDO1
SCHEMBL2032147 0.77 SMN1; SMN2 (0.52) SMN1; SMN2NPSR1PPARALOXL2IDO1
SCHEMBL7506690 0.76 SMN1; SMN2 (0.51) SMN1; SMN2NPSR1PPARALOXL2IDO1
SCHEMBL12585006 0.76 SMN1; SMN2 (0.55) SMN1; SMN2NPSR1PPARALOXL2IDO1
SCHEMBL31038096 0.75 FBP1 (0.74) SMN1; SMN2NPSR1MAPTFBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5814646-A TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS ELI LILLY AND COMPANY (US) 1998-09-29 — — US disclosed
US-5624937-A TREATMENT OF ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1997-04-29 — — US disclosed
Send feedback